however, myopathic alterations were only deteeted in dogs. In 3 separate studies consisting of an cscalating dose study in 2 dogs, a multiple dose study in 2 dogs, and an exploratory ultrastructural inves- tigation in a single dog, rolziracetam consistently produced skeletal muscle effects at 500 mg/kg when given for up to 14 days by oral administration in gelatin capsules. The studies were conducted in accordance with the current guidelines for animal welfare. Longer periods of drug administration were not conducted and additional animals were not used because development of the drug was suspended. The character of the lesion was consistent in all dogs but severity was quite variable.
Clinical signs were similar in the 3 studies. Typical signs that were observed in the repeated dose study in dogs given 500 mg/kg were red-discolored urine at Day 7, maintaining a prone position on Day 8, diarrhea on Day 9,'and emaciation, prostration, and hypothermia on Day 13. Because the dogs were caged, detailed gait abnormalities could not be evaluated. The dog in the ultrastructural investigation was removed from treatment for 4 days but no improvement in clinical condition was noted. Blood urea nitrogen and creatinine were elevated terminally reaching values of 114 and 2.3 IU, respectively. Alanine aminotransferase (ALT) and aspartic aminotransferase (AST) were increased above pretest and control values by Day 7 (Figs. 2 and 3) . Creatinine phosphokinase (CPK) principally of the MM isoenzyme was increased at Day 7 and continued to increase until termination in all dogs except 1 female of the multiple dose study ( Figs. 2 and 3) . In several instances, the values were 7,500-fold above pretest or control values ( Figs. 2 and 3) .
Significant lesions observed at necropsy were in kidney and urinary bladder, but were not detected in skeletal or cardiac muscle. The kidneys were dark red and the urinary bladder contained reddish-brown urine. The principal drug-related microscopic lesions were present in skeletal muscles. Urinary tract 
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changes were sequelae to myoglobinurea and the severity of the changes paralleled the myopathy. The myopathic lesions were most severe in the psoas muscle followed in descending order by the deltoid, rhomboideus, and biceps femoris.
Skeletal muscle lesions consisted of muhifocal degeneration and necrosis and included Zenker's necrosis, vacuolation of sarcoplasm, fragmentation, lysis of myofibrils, and occasionally fatty replacement and/or mineralization ( Figs. 4 and 5) . Acute inflammatory cell response, primarily neutrophils, was observed in only 1 dog of the escalating dose study. In several sections, sarcolemmal cell nodules intermixed within normal muscle fibers were the only observations and were considered hallmarks ofprevious myofiber degeneration and necrosis (Fig.  6 ). Cardiac lesions were not observed. Ultrastructural examinations by transmission electron microscopy of multiple sections (10 blocks examined) taken at the terminal sacrifice (Day 17) from the psoas muscle revealed a spectrum of nonspecific subcellular alterations consistent with the description of other myopathies. At low magnifications, myofibrils were replaced by homogeneous to flocculent electron dense material and Z-bands were disrupted (Fig. 7) . At higher magnifications, myonuclei appeared intact but mitochondria of these cells had variable degrees of change including lysis of cristae, matrical densities, and cristae crystalline inclusions. Mitochondria1 changes always coexisted with myofibrillar alterations.
The absence of macroscopic change in any of the aforementioned muscle masses, following intensive examination, is puzzling. The random, focal to multifocal distribution of the myopathy may explain the gross findings. The red discolored urine was the first sign in these studies, and was considered secondary to skeletal muscle damage. Increased levels of serum CPK, AST, and ALT were noted at the first collection point (Day 8) indicating the acute nature of the lesion. The increased values and high (>20) CPWAST ratio are characteristic of skeletal muscle damage rather than liver disease, in which the ratio is less than 1, or myocardial damage in which a ratio of 5 is generally observed (1). Rolziracetam is structurally unrelated to known myopathy-inducing agents.
Further, the enzyme biochemistry and morphologic characterization of this myopathy does not explain the mechanisms of action of this compound. These studies describe an unusual skeletal muscle toxicity and demonstrate the importance of critical 
